Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function
Levon M. Khachigian
Levon M. Khachigian
Published November 15, 2000
Citation Information: J Clin Invest. 2000;106(10):1189-1195. https://doi.org/10.1172/JCI11620.
View: Text | PDF
Perspective

Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function

  • Text
  • PDF
Abstract

Authors

Levon M. Khachigian

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Model of Egr-1–dependent response to injury. Injury to vascular cells re...
Model of Egr-1–dependent response to injury. Injury to vascular cells releases preformed endogenous growth factors (such as FGF-2), which activate Egr-1 gene expression in a paracrine manner via mitogen-activated protein kinases (MAPKs). Egr-1 protein can, in certain promoters, displace Sp1 from overlapping binding sites and increase the expression of pathophysiologically relevant genes whose products contribute to neointima formation. Rec, receptor.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts